Results 51 to 60 of about 6,560 (205)

Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients

Viruses, 2022
Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient molnupiravir use in kidney transplant recipients and hemodialysis patients
Paweł Poznański, Hanna Augustyniak-Bartosik, Anna Magiera-Żak, Karolina Skalec, Katarzyna Jakuszko, Oktawia Mazanowska, Dariusz Janczak, Magdalena Krajewska, Dorota Kamińska   +8 more
doaj   +1 more source

Molnupiravir. Vietnamese

, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 VIETNAMESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

Molnupiravir antiviral mechanism

, 2021
Molnupiravir, a prodrug of the nucleoside derivative β-D-N 4 -hydroxycytidine (NHC), is currently in clinical trials for COVID-19 therapy. However, the biochemical mechanisms involved in molnupiravirinduced mutagenesis had not been explored.
Menéndez-Arias, Luis
core   +1 more source

Molnupiravir. Russian

, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 RUSSIAN"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and may

core  

Recent Advances in Virus–Host Interactions, Antiviral Bioactive Compounds, and Breeding for Disease Resistance of Porcine Epidemic Diarrhea Virus

Animal Research and One Health, EarlyView.
Basic research on the PEDV infection cycle and virus–host interactions advances the development of anti‐PEDV drugs and disease‐resistant breeding and helps strengthen disease prevention and control while reducing economic losses in the swine industry.
Heyong Wu, Aosi Qi, Shuyu Zhong, Haozhen Du, Shimeng Guo, Hongsheng Ouyang, Hongming Yuan, Daxin Pang, Zicong Xie   +8 more
wiley   +1 more source

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Nature Communications
Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n = 253) or Usual Care (n = 
Joseph F. Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, Maximillian Woodall, Samuel Ellis, Akosua A. Agyeman, Charles Miller, Mercy Okechukwu, Emily Kirkpatrick, Amy I. Jacobs, Charlotte A. Williams, Sunando Roy, Luz M. Martin-Bernal, Rachel Williams, Claire M. Smith, Theo Sanderson, Fiona B. Ashford, Beena Emmanuel, Zaheer M. Afzal, Adrian Shields, Alex G. Richter, Jienchi Dorward, Oghenekome Gbinigie, Oliver Van Hecke, Mark Lown, Nick Francis, Bhautesh Jani, Duncan B. Richards, Najib M. Rahman, Ly-Mee Yu, Nicholas P. B. Thomas, Nigel D. Hart, Philip Evans, Monique Andersson, Gail Hayward, Kerenza Hood, Jonathan S. Nguyen-Van-Tam, Paul Little, F. D. Richard Hobbs, Saye Khoo, Christopher Butler, David M. Lowe, Judith Breuer, PANORAMIC Virology Group   +43 more
doaj   +1 more source

Differences in SARS‐CoV‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M. M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, on behalf of RECOVER‐Adult   +18 more
wiley   +1 more source

Molnupiravir. Portuguese

, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 PORTUGUESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

Population-Based Propensity Score-Matched Analysis of Paxlovid and Molnupiravir Effectiveness in High-Risk COVID-19 Patients

International Journal of Infectious Diseases
Introduction: COVID-19 poses a severe threat to high-risk populations, such as the elderly and those with incomplete vaccination. Despite the availability of treatments like Paxlovid and Molnupiravir, their relative effectiveness in preventing severe ...
Dr Yi-hsuan Chen, Dr Cheng-Yi Lee, Dr Hao-Yuan Cheng, Mr. Yu-Neng Cheuh, Mr. Hung-Wei Kuo   +4 more
doaj   +1 more source

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2390-2402, July 2026.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source